Hansen evaluated the combined use of COM902, an anti-TIGIT antibody, and a PD-L1 inhibitor in CT26 colon cancer and renca renal cancer models and found that the combination therapy significantly improved overall survival compared to PD-L1 inhibitor monotherapy [108]. This evidence concerns the gene CD274 and colonic neoplasm.